A new stabilized form of epinephrine with a pH of 7.4 has been developed * specifically for use in the management of open-angle glaucoma. It is a complex formula as a result of a reaction between epinephrine and boric acid. Its advantages over the forms of epinephrine now in use are that it is nonirritating to ocular tissues and is stable at room temperatures even after the bottle has been opened for more than a month. At least theoretically it has a greater physiologic activity than other forms of epinephrine, since it should penetrate the cornea more easily than the solutions of low pH now available. Also, the lack of irritation means less dilution of the drug by tears. A preliminary clinical trial on a small number of patients with open-angle glaucoma has yielded encouraging results.
Although there were several earlier reports of the use of epinephrine in the treatment of
VAUGHAN D, SHAFFER R, RIEGELMAN S. A New Stabilized Form of Epinephrine for the Treatment of Open-Angle Glaucoma. Arch Ophthalmol. 1961;66(2):232–235. doi:10.1001/archopht.1961.00960010234014
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: